Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHED-CM Intravenous Administration for ALS
jRCTs031230731Recruiting
- Sponsor
- U-Factor
- Start
- Mar 2024
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of SHED-CM in amyotrophic lateral sclerosis (ALS), sponsored by U-Factor. Primary endpoint: Safety assessment. Started Mar 2024; status: recruiting.
02
Drugs
SHED-CM
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCTs031230731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230731.